Cancer medicine · 2026
High Expression of SSEA3 and Globo H Predicts Poor Outcomes in Resected Extrahepatic Cholangiocarcinoma: A Single-Center Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hung Tsai-Hsien, Hung Jung-Tung, Yeh Chun-Nan, Hsieh Rodney Cheng-En, Hsu Sheng-Chi, Yu Alice L, Huang Yenlin
Аннотация
BACKGROUND: SSEA3, SSEA4, and Globo H glycosphingolipids have been implicated in tumor progression and immune modulation across various malignancies. However, their clinical significance in extrahepatic cholangiocarcinoma (eCCA) remains largely undefined. This study aimed to evaluate the expression levels and prognostic relevance of SSEA3, SSEA4, and Globo H in patients with eCCA.
METHODS: Immunohistochemical staining for SSEA3, SSEA4, and Globo H was performed on formalin-fixed, paraffin-embedded tumor samples from 175 patients with resected eCCA. Expression levels were quantified using H-scores, and optimal cut-off values determined from receiver operating characteristic curve analysis defined high and low expression groups. Kaplan-Meier analysis with log-rank test was used to evaluate relapse-free survival (RFS) and overall survival (OS), and Cox regression analysis identified independent prognostic factors.
RESULTS: Elevated expression of SSEA4 and Globo H was significantly associated with late stage of eCCA. Kaplan-Meier analysis revealed that high expression of all three glycans was significantly correlated with shorter RFS (all p < 0.001). Similar results were observed in patients with early stage. In multivariate Cox regression analysis, high expression of SSEA3 (HR = 2.77, 95% CI: 1.03-7.46, p = 0.044) and Globo H (HR = 2.88, 95% CI: 1.05-7.94, p = 0.040) independently predicted poor RFS.
CONCLUSION: SSEA3 and Globo H independently predict RFS. These findings support the potential prognostic relevance of Globo H and SSEA3 in eCCA; however, external validation and functional studies are required before clinical implementation or therapeutic translation.
METHODS: Immunohistochemical staining for SSEA3, SSEA4, and Globo H was performed on formalin-fixed, paraffin-embedded tumor samples from 175 patients with resected eCCA. Expression levels were quantified using H-scores, and optimal cut-off values determined from receiver operating characteristic curve analysis defined high and low expression groups. Kaplan-Meier analysis with log-rank test was used to evaluate relapse-free survival (RFS) and overall survival (OS), and Cox regression analysis identified independent prognostic factors.
RESULTS: Elevated expression of SSEA4 and Globo H was significantly associated with late stage of eCCA. Kaplan-Meier analysis revealed that high expression of all three glycans was significantly correlated with shorter RFS (all p < 0.001). Similar results were observed in patients with early stage. In multivariate Cox regression analysis, high expression of SSEA3 (HR = 2.77, 95% CI: 1.03-7.46, p = 0.044) and Globo H (HR = 2.88, 95% CI: 1.05-7.94, p = 0.040) independently predicted poor RFS.
CONCLUSION: SSEA3 and Globo H independently predict RFS. These findings support the potential prognostic relevance of Globo H and SSEA3 in eCCA; however, external validation and functional studies are required before clinical implementation or therapeutic translation.